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Aims The aim of this study was to describe incidence and determinants of left ventricular reverse remodelling (r-LVR) at
6 months follow-up after MitraClip implantation in patients with secondary severe mitral regurgitation (MR) and




Forty-five patients, undergoing MitralClip implantation with low ejection fraction and high surgical risk were enrolled
in this study. Three of them died before the scheduled 6 months follow-up period and one patient had cardiac sur-
gery due to MitraClip detachment. All patients underwent transthoracic 2D and 3D echocardiography before and
6 months after the procedure. A significant MR severity reduction and an improvement in New York Heart
Association (NYHA) class were detected in all patients. The study population was divided in two groups according
to the presence of r-LVR (51%, n = 23 patients) or not (non-rLVR group, 18 patients). Non-significant differences in
MR aetiology and number of clips implanted were found. Left ventricular reverse remodelling patients showed sig-
nificant lower values of logistic EuroSCORE and STS score, left ventricular end-diastolic volume index (LVEDV/i),
right ventricular end systolic area, and pulmonary artery systolic pressure (PASp) at baseline evaluation. At multivari-
able analysis, baseline PASp value resulted to be the only independent predictor of r-LVR [odds ratio 95% confi-
dence interval 0.94 (0.89–0.99), P = 0.021]. In r-LVR patients, a significant improvement in LVEF and global longitu-
dinal strain and a reduction in left atrial volume index were detected after 6 months, whereas in non-rLVR subgroup
a significant increase in both LVEDV/i and left ventricular end-systolic volume index was observed at follow-up.
...................................................................................................................................................................................................
Conclusion Even if a reduction of MR was detected in all patients after MitralClip implant, our findings suggest that end-stage
patients presenting with higher left ventricular volumes, logistic scores, and PASp may not benefit from the proced-
ure at longer follow-up in terms of left ventricular function.
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Introduction
Mitral regurgitation (MR) is the second most prevalent valvular dis-
ease in Europe. The disorder commonly evolves insidiously over
many years, causing progressive left atrial (LA) and left ventricular
(LV) dilatation and consequent deterioration of LV contractile func-
tion due to chronic volume overload. Despite optimal medical ther-
apy, severe secondary MR confers a worse prognosis.1,2
Mitral valve (MV) surgery (repair or replacement)3 is the current
standard of care for patients with severe symptomatic primary MR; it
* Corresponding author. Tel: þ39 06 49979048; Fax: þ39 06 49979060. E-mail: sara.cimino@uniroma1.it
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.


















































has been shown to result in potential reverse LA and LV remodelling (r-
LVR).4 However, due to the high operative risk, limited data are available
about therapeutic benefits of MV surgery in patients with heart failure
and secondary MR. Current guidelines only advocate a Class II indication
for MV surgery in symptomatic patients with chronic severe secondary
MR and severely reduced LV ejection fraction (LVEF) (<30%).3–5
The MitraClip device has evolved as a promising interventional
tool for MV repair in severe MR.6,7 The first randomized controlled
study (EVEREST II) demonstrated a superior safety of endovascular
valve edge-to-edge repair when compared with MV surgery, with a
similar improvement in clinical outcome.8,9 MitraClip might be a valid
therapeutic option for selected high-risk surgical patients with se-
verely reduced LV function. Several studies demonstrated encourag-
ing data about clinical and safety results after MitraClip implantation
in this high-risk subset of patients, however, it is yet to know whether
the reduction in MR leads to r-LVR, and ultimately improved progno-
sis, in the long-term. We sought to evaluate the determinants of
r-LVR at 6 months follow-up after MitraClip implantation.
Methods
Study population
From June 2014 to July 2017, 45 consecutive patients undergoing
percutaneous MV repair with the MitraClip system were enrolled
prospectively in this study. Inclusion criteria were: (i) a diagnosis of
severe secondary MR; (ii) reduced LV function (<45%); (iii) high surgi-
cal risk; and (iv) New York Heart Association (NYHA) Class III or IV.
Patients with MV morphological properties that would make
MitraClip implantation unlikely or unsuitable were excluded.9,10 The
MitraClip procedure was explained to the patients, as well as alterna-
tive options (medical treatment or high-risk MV surgery). The ‘Heart
Team’ evaluated patients and conventional surgery was excluded in
case of excessive morbidity and mortality (high logistic EuroSCORE
or STS score, or excessive comorbidities).9 The local ethics commit-
tee approved this study, and all patients provided written informed
consent.
Patients were on optimized medical therapy and were treated
with percutaneous angioplasty and stent implantation, implantable
cardioverter defibrillator, and cardiac resynchronization therapy
devices prior to MitraClip therapy, if clinically indicated. The baseline
and follow-up functional status was assessed according to the NYHA
criteria.
Echocardiography
All enrolled patients underwent transthoracic two- and three-
dimensional echocardiography (3DE) (Philips X5-1 Transducer,
EPIQ7C) before and at 6 months after the procedure of percutan-
eous MV repair. The presence of MR at baseline was qualified by col-
our Doppler and quantified by the vena contracta width and the
Proximal Isovelocity Surface Area method in accordance with the
.................................................................................................
Table 1 Baseline characteristics
Parameters Patients (n 5 45)
Age (years) 73 ± 7.7
Logistic EuroSCORE 13 ± 8.2
STS score 6 ± 5.6
Male sex, n (%) 22 (48)
Diabetes, n (%) 11 (24)
Hypertension, n (%) 36 (80)
Dyslipidaemia, n (%) 24 (53)
Previous AMI, n (%) 14 (31)
Previous PCI, n (%) 15 (33)
Previous CABG, n (%) 6 (13)
CRF, n (%) 12 (26)
NYHA III–IV, n (%) 45 (100)
Nitrates, n (%) 20 (44)
ACE-inhibitors/ARBs, n (%) 26 (58)
Ivabradine, n (%) 1 (0.02)
Beta-blockers, n (%) 42 (93)
Anticoagulants, n (%) 12 (26)
Antiplatelets, n (%) 24 (53)
Antialdosterone, n (%) 37 (83)
Diuretics, n (%) 45 (100)
Pacemaker, n (%) 12 (26)
AF, n (%) 10 (22)
Non-ischaemic aetiology, n (%) 29 (65)
Ischaemic aetiology, n (%) 16 (35)
ACE, angiotensin converting enzyme; AF, atrial fibrillation; AMI, acute myocardial
infarction; ARBs, angiotensin II receptor blockers; CABG, coronary artery bypass
grafting; CRF, chronic renal failure; NYHA, New York Heart Association; PCI,
percutaneous coronary intervention; STS, Society of Thoracic Surgery Score.
.................................................................................................
Table 2 Echocardiographic parameters at baseline







Regurgitant volume (mL) 51 ± 14.3 27 ± 8 <0.001
EROA (cm2) 0.37 ± 0.15 0.19 ± 0.06 0.023
Annulus diameter (mm) 37 ± 4.4 35 ± 3.7 0.026
E wave (cm/s) 117 ± 49 148 ± 49 NS
Septal e0 (cm/s) 5.1 ± 1.5 4.34 ± 3.1 NS
LVEF % 29 ± 11 29 ± 12 NS
LVEDV/i (mL/m2) 96 ± 24 93 ± 32 NS
LVESV/i (mL/m2) 68 ± 25 65 ± 30 NS
LA Vol/i (mL/m2) 54 ± 19 49 ± 19.3 NS
RA Vol/i (mL/m2) 41 ± 22.9 41 ± 31 NS
RV ED area (cm2) 17± 4.7 18± 6.8 NS
RV ES area (cm2) 11 ± 3.8 12 ± 5.8 NS
RV FAC % 36 ± 8.6 36 ± 6 NS
TAPSE (mm) 20 ± 3.6 21 ± 2.8 NS
PASp (mmHg) 44± 15.7 44 ± 14 NS
GLS % -6.4 ± 3.5 -7.3 ± 3.15 NS
ED, end-diastolic; ES, end-systolic; EROA, effective regurgitant orifice area; FAC,
fractional area change; GLS, global longitudinal strain; LA Vol/i, left atrium vol-
ume/index; LVEDV/i, left ventricular end-diastolic volume index; LVEF, left ven-
tricular ejection fraction; LVESV/i, left ventricular end-systolic volume index; NS,
not significant; PASp, pulmonary artery systolic pressure; RA Vol/i, right atrium
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Figure 1 Percentage of NYHA Class III–IV class at baseline and at 6 months follow-up.
....................................................................................................................................................................................................................
Table 3 Clinical and echocardiographic variables in r-LVR vs. non-rLVR patients at baseline
Parameters Non-rLVR (n 5 18) r-LVR (n 5 23) P-value
Age (years) 74 ± 6.4 72 ± 8.7 NS
EuroSCORE 17 ± 7.5 8.7 ± 7.4 0.001
STS score 8.6 ± 7 4.2 ± 3 0.014
Male sex, n (%) 7 (38) 12 (52) NS
Diabetes, n (%) 3 (16) 6 (26) NS
Hypertension, n (%) 15 (83) 20 (87) NS
Dyslipidaemia, n (%) 8 (44) 15 (65) NS
Previous AMI, n (%) 6 (33) 8 (34) NS
Previous PCI, n (%) 6 (33) 9 (39) NS
Previous CABG, n (%) 2 (11) 4 (17) NS
CRF, n (%) 5 (27) 6 (23) NS
Ischaemic aetiology, n (%) 6 (33) 8 (35) NS
Non-ischaemic aetiology, n (%) 12 (66) 15 (65) NS
Clips number (1), n (%) 10 (55) 12 (52) NS
Clips number (2), n (%) 8 (45) 10 (44) NS
Clips number (3), n (%) 0 (0) 1 (0.04) NS
Regurgitant volume (mL) 54.3 ± 17 46.3 ± 11 NS
EROA (cm2) 0.39 ± 0.1 0.33 ± 0.1 NS
Annulus diameter (mm) 37 ± 4.3 38.6 ± 4.5 NS
LVEF % 29.6 ± 8 28.5 ± 11 NS
LVEDV/i (mL/m2) 99 ± 20 91 ± 25 0.021
LVESV/i (mL/m2) 69 ± 24 65 ± 15 NS
LA Vol/i (mL/m2) 57 ± 13 52 ± 21 NS
RV ED area (cm2) 19.1± 4.9 16.2± 4 0.05
RV ES area (cm2) 12.3 ± 3.9 9.7 ± 3.14 0.026
RV FAC % 56.4 ± 7.1 38.7 ± 9.6 NS
TAPSE (mm) 19.5 ± 3.3 21.2 ± 3.7 NS
PASp (mmHg) 50.6 ± 16.5 39 ± 12.6 0.014
GLS % -6.7 ± 4.1 -6.12 ± 2.7 NS
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CRF, chronic renal failure; ED, end-diastolic; ES, end-systolic; EROA, effective regurgitant orifice area;
FAC, fractional area change; GLS, global longitudinal strain; LA Vol/i, left atrium volume/index; LVEDV/i, left ventricular end-diastolic volume index; LVEF, left ventricular ejec-
tion fraction; LVESV/i, left ventricular end-systolic volume index; NS, not significant; PASp, pulmonary artery systolic pressure; PCI, percutaneous coronary intervention; RV,
right ventricle; STS, Society of Thoracic Surgery Score; TAPSE, tricuspid annular plane excursion.
Bold values represent statistical significance of P values.























































.current guidelines.3 All patients were assigned a MR severity score of
1 (mild), 2 (mild to moderate), 3 (moderate to severe), or 4 (severe),
according to the quantitative measure of the effective regurgitant ori-
fice area (EROA) and regurgitant volume. The regurgitant volume
was estimated as the EROA multiplied by the velocity time integral of
the regurgitant jet. Procedural success was defined as the reduction
of the MR severity score to 2 or less after clip implantation. The fol-
lowing parameters were considered to evaluate the LV changes in
size and function: LV end-diastolic and end-systolic volume indexed
to body surface area (LVEDV/i and LVESV/i, respectively), and the
LVEF, obtained using 3DE (full volume function). Right ventricular
(RV) dimension and function and pulmonary artery systolic pressure
(PASp) were also assessed according to guidelines.11 Two-
dimensional speckle tracking analysis with global longitudinal strain
(GLS) was also obtained in all patients. LV reverse remodelling was
defined as a decrease >_10% in the LVESV/i at follow-up.12
Reproducibility
Intra-observer and inter-observer variability for the 3D manual meas-
urements of LVEF and LV volumes was assessed in a sample of 10
patients. Two investigators measured blinded the same 3DEcho
loops, and one investigator repeated the analysis 1 week later,
blinded to the previous measurements.
MitraClip procedure
All patients were undergone to endovascular edge-to-edge MV re-
pair as previously described.9,10 All procedures were performed
using the 24-Fr MitraClip device (Abbott Vascular, Santa Clara, CA,
USA). All clips were implanted under general anaesthesia and the
procedures were transoesophageal echocardiography guided.
Haemostasis was achieved by compression of the vein for 12 h.
Patients were treated with double antiplatelet therapy after the inter-
vention and oral anticoagulants where indicated.
Statistical analysis
Continuous variables are presented as mean ± standard deviation
and were compared using Student’s t-test or the Mann–Whitney
rank sum test for unpaired comparisons, as appropriate. The mean
differences between the baseline and 6-month echocardiographic
parameters are reported. The categorical variables are expressed as
counts and percentages and were compared using the v2 test or
Fisher exact test, as appropriate. Differences were considered statis-
tically significant when P < 0.05. Univariable and multivariable analyses
were performed with backward method to assess determinants of r-
LVR. Variables were included in the model when P < 0.10. Statistical
analyses were performed using the Statistical Package for Social
Sciences, version 23.0 (SPSS, Chicago, IL, USA). Interclass correlation
coefficients (ICCs) were calculated to assess inter-observer and
intra-observer agreement of 3DE measurements.
Results
Baseline characteristics
Baseline characteristics of the study population are depicted in
Table 1. Mean age was 73 ± 7.7 years. All patients were in NYHA
Class III–IV and about two-third of them had non-ischaemic cardio-
myopathy. Cardiac death occurred in 3 (6%) patients before the
scheduled follow-up; 1 patient underwent cardiac surgery after
3 months because of MitraClip detachment and 41 patients had a
complete 6 months follow-up echocardiogram.
.................................................................................................
Table 4 Echocardiographic parameters at baseline






Regurgitant volume (mL) 54 ± 17 29 ± 5 <0.001
EROA (cm2) 0.39 ± 0.1 0.21 ± 0.05 <0.001
LA Vol/i (mL/m2) 57 ± 13 53 ± 18 NS
LVEF% 29 ± 8 29 ± 15 NS
LVEDV/i (mL/m2) 99 ± 20 106 ±35 0.018
LVESV/i (mL/m2) 69 ± 24 75 ± 21 0.022
RV ED area (cm2) 19± 4.9 21 ± 6.8 NS
RV ES area (cm2) 12 ± 3.9 14 ± 6.4 NS
RV FAC % 56 ± 7.1 34 ± 8 NS
TAPSE (mm) 19 ± 3.3 20 ± 2.4 NS
PASp (mmHg) 50 ± 16.5 51 ± 12 NS
GLS % -6.7 ± 4.1 -7.7 ± 2.7 NS
ED, end-diastolic; ES, end-systolic; EROA, effective regurgitant orifice area; FAC,
fractional area change; GLS, global longitudinal strain; LA Vol/i, left atrium vol-
ume/index; LVEDV/i, left ventricular end-diastolic volume index; LVEF, left ven-
tricular ejection fraction; LVESV/i, left ventricular end-systolic volume index; NS,
not significant; PASp, pulmonary artery systolic pressure; RV, right ventricle; SD,
standard deviation; TAPSE, tricuspid annular plane excursion.
Bold values represent statistical significance of P values.
.................................................................................................
Table 5 Echocardiographic parameters at baseline






Regurgitant volume (mL) 46 ± 11 25 ± 9.3 <0.001
EROA (cm2) 0.33 ± 0.1 0.19 ± 0.07 <0.001
LA Vol/i (mL/m2) 52 ± 21 44.9 ± 18 0.017
LVEF % 28.5 ± 11 32 ± 8.4 0.048
LVEDV/i (mL/m2) 91 ± 25 85 ± 23 <0.001
LVESV/i (mL/m2) 65 ± 15 57 ± 20 <0.001
RV ED area (cm2) 16.2 ± 4 17.1 ± 6 NS
RV ES area (cm2) 9.7 ± 3.14 11.3 ± 5 NS
RV FAC % 38.7 ± 9.6 36.6 ± 5.2 NS
TAPSE (mm) 21.2 ± 3.7 22.4 ± 2.7 NS
PASp (mmHg) 39 ± 12.6 39.9 ± 13 NS
GLS % -6.12 ± 2.7 -8.5 ± 3.3 <0.001
ED, end-diastolic; ES, end-systolic; EROA, effective regurgitant orifice area; FAC,
fractional area change; GLS, global longitudinal strain; LA Vol/i, left atrium vol-
ume/index; LVEDV/i, left ventricular end-diastolic volume index; LVEF, left ven-
tricular ejection fraction; LVESV/i, left ventricular end-systolic volume index; NS,
not significant; PASp, pulmonary artery systolic pressure; RV, right ventricle; SD,
standard deviation; TAPSE, tricuspid annular plane excursion.
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Figure 2 (A) LV volumes changes in a patient with r-LVR. (B) LV volumes changes in a patient without r-LVR.




































































Changes in NYHA class, MR severity and
LV volumes after MitraClip implantation
Echocardiographic parameters at baseline and at 6 months follow-up
in the overall cohort of patients are depicted in Table 2. By definition,
all patients had severe MR at baseline. No significant changes were
observed in LV volumes and LVEF after implant. Noteworthy, a sig-
nificant MR reduction was observed after implantation in all patients.
Similarly, a significant improvement in NYHA functional class was
detected after MitraClip implantation, as showed in Figure 1. LV re-
verse remodelling occurred in 23 patients (56%), whereas 18 patients
did not present reverse remodelling (non-rLVR 44%), as showed in
Table 3. At baseline, non-rLVR patients showed higher values of
logistic EuroSCORE, STS score, LVEDV/i, RV end systolic area, and
PASp when compared with r-LVR subgroup. In these patients, a sig-
nificant increase in both LVEDV/i and LVESV/i was observed at 6
months follow-up (Table 4). On the contrary, r-LVR patients showed
a significant improvement in LVEF and in GLS and a reduction in LA
volume index after 6 months (Table 5). Figure 2 shows an example of
volumes changes in a patient with r-LVR (A) and a patient without
r-LVR (B).
Determinants of LV remodelling
Table 3 compared patients with and without LVR. No significant dif-
ferences in the MR aetiology and the number of clip implanted were
found between the two groups. Non-significant MV stenosis and
interatrial shunt was detected after the intervention in both groups.
Univariable determinants of r-LVR were STS score (P = 0.036),
EuroSCORE (P = 0.036), LVEDV/i (P = 0.043), RV end-systolic area
(P = 0.043), and PASp (P = 0.010). On multivariable analysis, baseline
PASp [P = 0.021; odds ratio 0.94, 95% confidence interval (CI) 0.89–
0.99] resulted to be the only independent predictor of r-LVR, as
showed in Table 6.
Reproducibility
Intra-observer agreement analysis showed an ICC of 0.981
(P < 0.001, 95% CI 0.92–0.996) for LVEF measurements, of 0.996
(P < 0.001, 95% CI 0.985–0.999) for LVEDV/i measurements, and of
0.998 (P < 0.001, 95% CI 0.992–0.999) for LVESV/i measurements.
Inter-observer agreement analysis showed an ICC of 0.938
(P < 0.001, 95% CI 0.75–0.996) for LVEF measurements, of 0.994
(P < 0.001, 95% CI 0.736–0.999) for LVEDV/i measurements, and of
0.997 (P < 0.001, 95% CI 0.986–0.999) for LVESV/i measurements
(Table 7).
Discussion
Secondary MR is a common finding in patients with heart failure with
reduced ejection fraction and dilated LV, leading to progressive
chamber dilatation, functional deterioration and increased mortality
risk.13 MitraClip is an effective procedure to reduce the cardiac over-
load from severe MR. However, current criteria for subjects’ selec-
tion are based on MV characteristic only, irrespective of LV and RV
geometry and function.
This study showed that successful MitraClip procedure significantly
reduced MR severity and improved functional NYHA class, in line
with previously published data,14–17 consistently with MR reduction.
However, reverse remodelling occurred, at follow-up, only in 56% of
patients with severe MR and low LVEF, with a parallel improvement
in GLS. Lower pulmonary pressures, smaller LV volume and lower
logistic risk scores were the main determinants of reverse LV remod-
elling after MV repair. Previous studies showed significant benefits of
MitraClip procedure in patients with preserved LVEF9,10 and encour-
aging data in terms of safety and feasibility in patients with reduced
LV function.18 Scandura et al.19 observed a significant improvement in
LVEF and a significant r-LVR in a population composed of both pri-
mary and secondary MR. Rammos et al.20 demonstrated both r-LVR
and atrial remodelling with consequent improvement in GLS after
MitraClip implantation in a series of patients with an average value of
LVEF of 40.5 ± 2.5%. Pleger et al.15–18 also observed a significant
r-LVR in patients with severely reduced LVEF.21 In line with previous
studies, this study confirms the good results in terms of MR reduction
in the whole group of patients with low LVEF. However, percutan-
eous MV repair is accompanied by reverse remodelling only in specif-
ic subgroups of heart failure patients. As in our study, a significant
.................................... ....................................
.................................................................................................
Table 6 Univariable and multivariable determinants
of r-LVR
Univariate analysis Multivariate analysis
Variables OR (95% CI) P-value OR (95% CI) P-value
STS score 0.83 (0.7–0.9) 0.036









0.76 (0.61–0.93) 0.010 0.94 (0.89–0.99) 0.021
CI, confidence interval; ES, end-systolic; RV, right ventricle; PASp, pulmonary ar-
tery systolic pressure; STS, Society of Thoracic Surgery Score.
Bold values represent statistical significance of P values.
.................................................................................................


















LVEDV/i, left ventricular end-diastolic volume index; LVEF, left ventricular ejec-












































































































..improvement in both 2D and 3D GLS after MitraClip implantation
was recently demonstrated22 only in patients with less RV impair-
ment at baseline. We found that 44% of our subjects did not experi-
ence a reverse remodelling at follow-up. These patients had higher
risk scores, greater LV volume, more important RV impairment and
increased pulmonary pressure at baseline. Most of them had progres-
sion of LV dilatation over time. So, our data would be useful to iden-
tify a subset of patients in which MitraClip intervention will not
provide the significant expected benefits and will not change the nat-
ural history of the heart failure progression and ultimately the
prognosis.
Limitations
Major limitation of the study is the short follow-up observation. The
absence of events during follow-up precludes showing any associ-
ation between the lack of reverse remodelling and outcome. It would
be interesting to extend the follow-up to look at long-term outcome
and possibly further cardiac changes. Another important limitation is
the small sample size of the study that could mask other differences
between groups.
Conclusions
Percutaneous MV repair using MitraClip system allows reduction in
MR and NYHA. However, reverse remodelling occurs few months
after the intervention only in patients with less severe baseline LV
dilatation, lower pulmonary pressures, and lower logistic risk score.
Our findings suggest that end-stage heart failure patients, presenting
before the intervention with higher LV volumes and pulmonary pres-
sure may not benefit from the procedure at long-term follow-up.
Further studies with greater number of patients and longer follow-up
are needed to confirm these data.
Conflict of interest: none declared.
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